Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Sponsor

University of California, Davis (Other)

Overall Status

Completed

CT.gov ID

NCT02240719

Collaborator

Novartis (Industry)

Enrollment

Location

Arm

42.3

Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase I trial studies the side effects and the best dose of everolimus when given together with bendamustine hydrochloride in treating patients with cancer of the blood (hematologic cancer) that has returned after a period of improvement (relapsed) or did not get better with a particular treatment (refractory). Everolimus may prevent cancer cells from growing by blocking a protein that is needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving everolimus together with bendamustine hydrochloride may be a better treatment for hematologic cancer.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Refractory Chronic Lymphocytic Leukemia Multiple Myeloma	Drug: everolimus Drug: bendamustine hydrochloride	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

To determine the maximum tolerated dose (MTD) of everolimus when administered in combination with bendamustine (bendamustine hydrochloride) in defined hematologic malignancies.
To determine the safety and tolerability of administering everolimus in combination with bendamustine chemotherapy.

SECONDARY OBJECTIVES:

To determine the efficacy of everolimus when administered in combination with bendamustine in adult patients with relapsed/refractory hematological malignancies.

OUTLINE: This is a dose-escalation study of everolimus.

Patients receive bendamustine hydrochloride intravenously (IV) over 30 minutes on days 1 and 2 and everolimus orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Study Design

Study Type:

Interventional

Actual Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies

Study Start Date :

Oct 1, 2014

Actual Primary Completion Date :

Apr 9, 2018

Actual Study Completion Date :

Apr 9, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Everolimus + Bendamustine Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Drug: everolimus Given PO Other Names: 42-O-(2-hydroxy)ethyl rapamycin Afinitor RAD001 Drug: bendamustine hydrochloride Given IV Other Names: bendamustin hydrochloride bendamustine cytostasan hydrochloride Treanda

Arm

Intervention/Treatment

Experimental: Everolimus + Bendamustine

Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: everolimus

Given PO

Other Names:

42-O-(2-hydroxy)ethyl rapamycin

Afinitor

RAD001

Drug: bendamustine hydrochloride

Given IV

Other Names:

bendamustin hydrochloride

bendamustine

cytostasan hydrochloride

Treanda

Outcome Measures

Primary Outcome Measures

MTD of everolimus, defined as the dose that produces dose-limiting toxicity (DLT) in =< 1/6 patients, determined by incidence of DLT graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [28 days]
The toxicities observed at each dose level will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity (by NCI CTCAE version 4.0) and nadir or maximum values for the laboratory measures, time of onset (i.e. course number), duration, and reversibility or outcome. Tables will be created to summarize these toxicities and side effects by dose and by course.

Secondary Outcome Measures

Incidence and severity of adverse events as defined by the NCI CTCAE version 4.03 [Up to 30 days post-treatment]
Response rates (complete response, partial response, stable disease) [Up to 30 days post-treatment]
Response rate among patients with measurable disease will be summarized by exact binomial confidence intervals.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Measurable disease
Baseline hemoglobin level of > 7.0 g/dl
Understand and voluntarily sign an informed consent form
Able to adhere to the study visit schedule and other protocol requirements
All the patients need to have biopsy proven active disease at the time of clinical trial
Eastern Cooperative Oncology Group performance status of =< 2 study entry
Absolute neutrophil count >= 1,000/mm^3
Platelet count >= 50,000/mm^3
Calculated creatinine clearance > 40 ml/min or 24 hour urine
Total bilirubin =< 2 x upper limit of normal
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x upper limit of normal
International normalized ratio < 2

Exclusion Criteria:

Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
Currently part of or have participated in any clinical investigation with an investigational drug within 1 month prior to dosing
Any severe and/or uncontrolled medical conditions
Uncontrolled diabetes mellitus
Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
Currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of everolimus
Known hypersensitivity to everolimus or bendamustine
Known central nervous system (CNS) disease (NHL, diffuse large B cell lymphoma [DLBCL])
Recent major surgery within 14 days prior to cycle 1, day 1
Taking strong cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors
Received live attenuated vaccines
Known sero-positive for active or past viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
History of another primary malignancy
History of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
Pregnant or nursing (lactating) women
Women of childbearing potential
Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization; in the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential
Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment